KR102947335B1 - 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절 - Google Patents

최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Info

Publication number
KR102947335B1
KR102947335B1 KR1020247017683A KR20247017683A KR102947335B1 KR 102947335 B1 KR102947335 B1 KR 102947335B1 KR 1020247017683 A KR1020247017683 A KR 1020247017683A KR 20247017683 A KR20247017683 A KR 20247017683A KR 102947335 B1 KR102947335 B1 KR 102947335B1
Authority
KR
South Korea
Prior art keywords
fgf23
krn23
serum
subjects
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247017683A
Other languages
English (en)
Korean (ko)
Other versions
KR20240093956A (ko
Inventor
에밀 카키스
마르틴 하비에르 산
도모히로 스도
Original Assignee
울트라제닉스 파마수티컬 인코포레이티드
쿄와 기린 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울트라제닉스 파마수티컬 인코포레이티드, 쿄와 기린 가부시키가이샤 filed Critical 울트라제닉스 파마수티컬 인코포레이티드
Priority to KR1020267009825A priority Critical patent/KR20260051107A/ko
Publication of KR20240093956A publication Critical patent/KR20240093956A/ko
Application granted granted Critical
Publication of KR102947335B1 publication Critical patent/KR102947335B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020247017683A 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절 Active KR102947335B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267009825A KR20260051107A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462009474P 2014-06-09 2014-06-09
US62/009,474 2014-06-09
PCT/US2015/033226 WO2015191312A1 (en) 2014-06-09 2015-05-29 The effective and efficient control of serum phosphate for optimal bone formation
KR1020217024284A KR20210099180A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024284A Division KR20210099180A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267009825A Division KR20260051107A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Publications (2)

Publication Number Publication Date
KR20240093956A KR20240093956A (ko) 2024-06-24
KR102947335B1 true KR102947335B1 (ko) 2026-04-03

Family

ID=54769049

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247017683A Active KR102947335B1 (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
KR1020177000293A Ceased KR20170013993A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
KR1020217024284A Ceased KR20210099180A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
KR1020267009825A Pending KR20260051107A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020177000293A Ceased KR20170013993A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
KR1020217024284A Ceased KR20210099180A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
KR1020267009825A Pending KR20260051107A (ko) 2014-06-09 2015-05-29 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절

Country Status (25)

Country Link
US (5) US10639360B2 (https=)
EP (3) EP3845245B1 (https=)
JP (2) JP6808493B2 (https=)
KR (4) KR102947335B1 (https=)
CN (1) CN106604743A (https=)
AR (2) AR100689A1 (https=)
AU (1) AU2015275128C1 (https=)
BR (2) BR112016028567A2 (https=)
CA (1) CA2949234C (https=)
CL (1) CL2016003179A1 (https=)
CY (1) CY1124328T1 (https=)
DK (2) DK3151859T3 (https=)
ES (2) ES3040805T3 (https=)
FI (1) FI3845245T3 (https=)
HR (2) HRP20210250T1 (https=)
HU (2) HUE053271T2 (https=)
LT (2) LT3845245T (https=)
MX (2) MX381052B (https=)
PE (1) PE20170248A1 (https=)
PL (2) PL3845245T3 (https=)
PT (2) PT3845245T (https=)
RS (2) RS61443B1 (https=)
SI (2) SI3151859T1 (https=)
SM (2) SMT202500342T1 (https=)
WO (1) WO2015191312A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CN106709662B (zh) * 2016-12-30 2021-07-02 山东鲁能软件技术有限公司 一种电力设备运行工况划分方法
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
BR112021019337A2 (pt) * 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
EP4676955A2 (en) * 2023-03-10 2026-01-14 Ultragenyx Pharmaceutical Inc. Human fgf23-binding antibodies with improved affinity and efficacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU2005202100A1 (en) 1999-05-11 2005-06-09 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (en) 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4527982B2 (ja) * 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
US8158725B2 (en) 2005-08-22 2012-04-17 Bridgestone Corporation Functionalized polymers and tires therefrom
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063067A2 (en) * 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
WO2013074738A1 (en) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
CA2949234A1 (en) 2015-12-17
MX2021003740A (es) 2021-05-27
ES3040805T3 (en) 2025-11-05
JP2017524656A (ja) 2017-08-31
RS61443B1 (sr) 2021-03-31
SI3845245T1 (sl) 2025-10-30
PL3845245T3 (pl) 2025-12-22
LT3845245T (lt) 2025-09-25
EP3151859B1 (en) 2020-11-25
WO2015191312A1 (en) 2015-12-17
PT3845245T (pt) 2025-09-16
AR100689A1 (es) 2016-10-26
US10639360B2 (en) 2020-05-05
BR112016028567A2 (pt) 2018-01-30
KR20170013993A (ko) 2017-02-07
US20260035449A1 (en) 2026-02-05
EP3845245A1 (en) 2021-07-07
HRP20251099T1 (hr) 2025-11-07
JP2021050226A (ja) 2021-04-01
SI3151859T1 (sl) 2021-06-30
PT3151859T (pt) 2021-02-03
US20200330575A1 (en) 2020-10-22
SMT202500342T1 (it) 2025-11-10
ES2851674T3 (es) 2021-09-08
KR20210099180A (ko) 2021-08-11
US11771748B2 (en) 2023-10-03
CN106604743A (zh) 2017-04-26
KR20260051107A (ko) 2026-04-15
HUE073105T2 (hu) 2025-12-28
LT3151859T (lt) 2021-03-25
JP6993490B2 (ja) 2022-02-03
SMT202100096T1 (it) 2021-03-15
EP4647444A3 (en) 2026-01-21
US12358976B2 (en) 2025-07-15
US20220133871A1 (en) 2022-05-05
MX2016016296A (es) 2017-10-12
EP3151859A4 (en) 2018-01-17
KR20240093956A (ko) 2024-06-24
EP3845245B1 (en) 2025-06-25
HRP20210250T1 (hr) 2021-04-02
CA2949234C (en) 2022-03-22
US20240115683A1 (en) 2024-04-11
DK3151859T3 (da) 2021-02-15
US20150353633A1 (en) 2015-12-10
EP3151859A1 (en) 2017-04-12
EP4647444A2 (en) 2025-11-12
CL2016003179A1 (es) 2017-11-03
HUE053271T2 (hu) 2021-06-28
PE20170248A1 (es) 2017-04-14
AU2015275128A1 (en) 2016-12-08
BR122023023102A2 (pt) 2024-03-05
JP6808493B2 (ja) 2021-01-06
FI3845245T3 (fi) 2025-09-09
AR131056A2 (es) 2025-02-12
RS67294B1 (sr) 2025-11-28
PL3151859T3 (pl) 2021-07-26
DK3845245T3 (da) 2025-09-15
AU2015275128C1 (en) 2020-02-13
AU2015275128B2 (en) 2019-10-31
US11202822B2 (en) 2021-12-21
MX381052B (es) 2025-03-12
CY1124328T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
US12358976B2 (en) Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
TWI526222B (zh) 抑制骨再吸收的方法
AU2008266745B2 (en) Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
EP2165716B1 (en) Novel bone mass increasing agent
AU2010305281A1 (en) Siglec 15 antibodies in treating bone loss-related disease
CN102548573B (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
AU2017225906A1 (en) Methods of treating bone diseases, disorders and/or injuries and reagents therefor
AU780470B2 (en) Inhibitor of osteoclast precursor formation
WO2026082814A1 (en) Anti- igfbp7 antibodies and uses thereof
CN116867803A (zh) 用于兽用的TNFα和NGF抗体
HK40006910A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or ant-adm non-ig scaffold for use in therapy

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)